Verustat Expands Service With DCT Support
Verustat has expanded its services to provide multiple levels of support for decentralized clinical trials (DCT). Verustat's customizable SELECT DCT offering is a streamlined solution that can offer increased compliance, stability, and accuracy.
The DCT program was designed to enhance the patient experience and improve compliance at the patient’s home. Each DCT can be customized to the patient’s requirements. Service offerings include Verustat’s RPM platform, telemedicine visits, medical peripheral hardware sourcing, multiple communication methods, global customs management, Tier 2 technical support, and equipment leasing.
Read more about Verustat here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
